49 results
6-K
EX-99.2
AMYT
Amryt Pharma Plc
12 Apr 23
Current report (foreign)
5:28pm
in respect of a Specified Company Share Option.
“Option Deficit Amount” means $0.036.
“Permitted Transfer” means a transfer of CVRs (a) upon death … of a Holder by will or intestacy or by instrument to an inter vivos or testamentary trust in which the CVRs are to be passed to beneficiaries upon the death
6-K
EX-99.5
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
and risk of premature death.
About AmrytAmryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing
6-K
EX-99.2
AMYT
Amryt Pharma Plc
4 Aug 22
Results of Annual General Meeting
7:38am
of premature death. The global market opportunity for EB is estimated by the Company to be in excess of $1.0 billion.
About AmrytAmryt is a global commercial
6-K
EX-99.1
AMYT
Amryt Pharma Plc
24 Jun 22
Filsuvez® recently approved by the European Commission for the treatment of EB
7:18am
of the esophagus and mucous membranes, a high risk of developing aggressive squamous cell carcinomas, infections and risk of premature death. The global market
6-K
EX-99.1
AMYT
Amryt Pharma Plc
23 Jun 22
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB
7:26am
, a high risk of developing aggressive squamous cell carcinomas, infections and risk of premature death. The global market opportunity for EB
6-K
EX-99.4
sjxcd93l
11 May 22
Current report (foreign)
4:30pm
424B3
qvx9lxj dq6qeou66
31 Mar 22
Prospectus supplement
8:44am
424B3
vwwqe7rfn7
31 Mar 22
Prospectus supplement
8:44am
6-K
EX-99.3
gsmgwrvoh5r4h5 5g7sz
31 Mar 22
Results of General Meeting
8:41am
424B3
aph bqh9fgex8f
28 Feb 22
Prospectus supplement
12:02pm
424B3
f1hh8s2 uqx8
28 Feb 22
Prospectus supplement
12:01pm
6-K
EX-99.1
4akku6yabzx ujhzvtb2
28 Feb 22
Amryt Receives Complete Response Letter from the FDA for Oleogel-S10 NDA
12:00pm
424B3
qbxcwatq0jj
31 Jan 22
Prospectus supplement
7:35am
424B3
iu5mfc3k4 ko4
31 Jan 22
Prospectus supplement
7:33am
6-K
EX-99.6
f43m39lselxab
31 Jan 22
Current report (foreign)
7:32am
424B3
13ate
23 Nov 21
Prospectus supplement
8:06am